invIOs to present data from clinical stage Cbl-b program at SITC 2022 invIOs GmbH announces that two abstracts on its clinical stage lead program, APN401, have been accepted for poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer being held in Boston, MA, on November 8-12, 2022. Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility Ultimovacs ASA presented clinical endpoints and biomarker results from patients in the UV1-103 phase I trial, at the 19th International Conference of the Society for Melanoma Research, being held 17-20 October in Edinburgh, UK. BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs BD, a leading global medical technology company, and Biocorp, a medical device and delivery systems manufacturer based in France, announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics. iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis iNtRON Biotechnology has announced that the Company has established the 2nd generation technology of Robot Bacteriophage development. bioLytical Laboratories Inc. receives WHO PQ for its iStatis COVID-19 Antigen Home Test bioLytical Laboratories Inc., a global leader in rapid in-vitro medical diagnostics, announced it has received its WHO PQ for its self-test, the iStatis COVID-19 Antigen Home Test, allowing its immediate entry into international markets. ImmVira announced to launch the construction of Global R&D and Commercialization Base On October 18, 2022, ImmVira launched the construction of its Global R&D and Commercialization Base in Suzhou Wuzhong Biomedical Industrial Park, China. Vitrolife AB: Conference call interim report - October 18, 2022 Invitation to attend Vitrolife AB conference call regarding presentation of the interim report January - September 2022. InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022 InxMed Co., Ltd is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase, alone or in combination with cobimetinib in patients with Uveal Melanoma and NRAS-mutant melanoma. Notice of Extra General Meeting in Biovica International AB - October 18, 2022 Biovica International The shareholders of Biovica International AB, reg. no. 556774-6150, are hereby invited to the extra general meeting to be held on Monday 7 November 2022, at 13.00 CET at Baker & McKenzie Advokatbyrå's premises at Vasagatan 7 in Stockholm. Silk Road Medical Announces Certain Preliminary Financial Data For Quarter Ended September 30, 2022 Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced certain preliminary financial data for the quarter ended September 30, 2022. AlzeCure gets New Abstract Accepted on ACD856's Indicative Disease-Modifying Effects Against Alzheimer's AlzeCure Pharma announced that an abstract on NeuroRestore ACD856 and its potential disease-modifying properties has been accepted for presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in San Francisco, November 29 - December 2. XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment XPhyto Therapeutics Corp. is pleased to report the results of its Rotigotine transdermal patch human skin cadaver study and dissolution data. Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World Evotec SE announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World. Angle PLC Announces Streamlining of Operations to Increase Cash Runway ANGLE plc, a world-leading liquid biopsy company, announces that the Board has taken the decision to close the Company's facilities in Toronto, Canada in an orderly wind down.
Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers.